3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
4
Gynecologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Lung Neoplasms
26
Carcinoma, Non-Small-Cell Lung
15
Small Cell Lung Carcinoma
4
Esophageal Neoplasms
4
Prostatic Neoplasms
3
Melanoma
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Rectal Neoplasms
2
Pulmonary Disease, Chronic Obstructive
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Tuberculosis
1
Tobacco Use Disorder
1
Thyroid Neoplasms
1
Thoracic Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Rhabdomyosarcoma
1
Precancerous Conditions
1
Pneumonia
1
Pleural Effusion, Malignant
1
Interventions
pembrolizumab
48
Carboplatin
34
Pemetrexed
28
Cisplatin
25
Docetaxel
23
Nivolumab
21
Paclitaxel
20
Gemcitabine
15
Magnetic Resonance Spectroscopy
14
Specimen Handling
12
Radiotherapy
12
Cyclophosphamide
12
Radiosurgery
11
130-nm albumin-bound paclitaxel
11
Erlotinib Hydrochloride
10
Bevacizumab
10
osimertinib
9
Cetuximab
8
Temozolomide
7
Taxes
7
Ipilimumab
7
Biopsy
7
fludarabine
6
Ramucirumab
6
Radiation
6
veliparib
5
tislelizumab
5
durvalumab
5
cemiplimab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
X-Rays
×
Thoracic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled